Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a ...

A synthetic microbiome therapy, tested in mice, protects against severe symptoms of a gut infection that is notoriously ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality ...

difficile treatment. Oral FZ002 is a live yeast genetically modified to express a tetraspecific anti-toxin for C. difficile in the gastrointestinal (GI) tract. FZ002 is a first-in-class multi ...

For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) ...

A federally-funded study published in Infection Control & Hospital Epidemiology demonstrates the efficacy of ...

A new UConn study reveals that tagatose, a plant-based sugar alternative, shows promise in mitigating Clostridioides difficile (C. difficile) infection, particularly those resistant to antibiotics.

The team developed the treatment for Clostridioides difficile, or C. difficile, a bacterium that can cause severe diarrhea, ...

Fintel reports that on March 12, 2025, Evercore ISI Group initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

difficile spores, respectively, after four hours of contact. Even in the presence of organic material, which can impede antimicrobial efficacy, EOS CU surfaces showed over 91% spore reduction.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...